Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 11;11(1):ofad633.
doi: 10.1093/ofid/ofad633. eCollection 2024 Jan.

False-Positive Human Immunodeficiency Virus Nucleic Acid Amplification Test After Chimeric Antigen Receptor T-Cell Therapy With Ciltacabtagene Autoleucel

Vishakh C Keri  1 , Mary Vito Topulli  2 , Abhinav Deol  2 , Joseph Uberti  2 , Hossein Salimnia  3 , Pranatharthi H Chandrasekar  1   2
Affiliations

False-Positive Human Immunodeficiency Virus Nucleic Acid Amplification Test After Chimeric Antigen Receptor T-Cell Therapy With Ciltacabtagene Autoleucel

Vishakh C Keri et al. Open Forum Infect Dis. .

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel therapeutic option for hematologic malignancies. Human immunodeficiency virus (HIV) nucleic acid amplification tests (NAATs) amplifying 5' long terminal repeat and gag genes cross-react with lentiviral vector-based CAR T-cell products. Cross-reactivity between CAR T-cell products and HIV NAATs may lead to false-positive test results.

Keywords: CAR T-cell therapy; ciltacabtagene autoleucel; human immunodeficiency virus nucleic acid amplification test.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts.

References

    1. Gill S, Brudno JN. CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions. Am Soc Clin Oncol Educ Book 2021; 41:1–20. - PubMed
    1. Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Cancer Lett 2023; 553:215949. - PubMed
    1. Mazinani M, Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components. Biomarker Res 2022; 10:70. - PMC - PubMed
    1. US Food and Drug Administration . CARVYKTI (ciltacabtagene autoleucel) package insert. Available at: https://www.fda.gov/media/156560/download. Accessed 9 September 2023.
    1. Villalba JA, Maus MV, Frigault MJ, et al. . False-positive human immunodeficiency virus test results in patients receiving lentivirus-based chimeric antigen receptor T-cell therapy: case report, review of the literature, and proposed recommendations. J Infect Dis 2022; 225:1933–6. - PubMed